These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14534528)

  • 1. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells.
    Knauf JA; Ouyang B; Croyle M; Kimura E; Fagin JA
    Oncogene; 2003 Oct; 22(44):6830-8. PubMed ID: 14534528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.
    Puxeddu E; Knauf JA; Sartor MA; Mitsutake N; Smith EP; Medvedovic M; Tomlinson CR; Moretti S; Fagin JA
    Endocr Relat Cancer; 2005 Jun; 12(2):319-34. PubMed ID: 15947106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
    Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
    Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
    Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM
    Oncogene; 2004 Aug; 23(35):5958-67. PubMed ID: 15184868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
    Wang J; Knauf JA; Basu S; Puxeddu E; Kuroda H; Santoro M; Fusco A; Fagin JA
    Mol Endocrinol; 2003 Jul; 17(7):1425-36. PubMed ID: 12690093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.
    Puxeddu E; Mitsutake N; Knauf JA; Moretti S; Kim HW; Seta KA; Brockman D; Myatt L; Millhorn DE; Fagin JA
    J Biol Chem; 2003 Dec; 278(52):52131-8. PubMed ID: 14555660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
    Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
    Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
    Celetti A; Cerrato A; Merolla F; Vitagliano D; Vecchio G; Grieco M
    Oncogene; 2004 Jan; 23(1):109-21. PubMed ID: 14712216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET oncogene activation in papillary thyroid carcinoma.
    Tallini G; Asa SL
    Adv Anat Pathol; 2001 Nov; 8(6):345-54. PubMed ID: 11707626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
    Knauf JA; Kuroda H; Basu S; Fagin JA
    Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
    Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
    Mitsutake N; Knauf JA; Mitsutake S; Mesa C; Zhang L; Fagin JA
    Cancer Res; 2005 Mar; 65(6):2465-73. PubMed ID: 15781663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
    Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
    Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
    Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
    Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.